Phase 3 Clinical Trials With Primary Completion Dates in February 2016

This is a list of Phase 3 trials with primary completion dates in February 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AGRX Agile Therapeutics, Inc. 2016-02-01 Phase 3 NCT02158572 Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System
ALKS Alkermes plc 2016-02-01 Phase 3 NCT02158533 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
AMPE Ampio Pharmaceuticals, Inc. 2016-02-01 Phase 3 NCT02556710 Study to Evaluate the Efficacy And Safety Of An Intra-Articular Injection Of Ampionâ„¢ In Adults With Pain With Osteoarthritis Of The Knee
CPIX Cumberland Pharmaceuticals Inc. 2016-02-01 Phase 3 NCT01451411 A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
CTIC CTI BioPharma Corp. 2016-02-01 Phase 3 NCT02055781 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
EARS Auris Medical Holding AG 2016-02-01 Phase 3 NCT02040194 AM-101 in the Treatment of Acute Tinnitus 3
MSTX Mast Therapeutics, Inc. 2016-02-01 Phase 3 NCT01737814 Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
THLD Threshold Pharmaceuticals, Inc. 2016-02-01 Phase 3 NCT01746979 Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
TTPH Tetraphase Pharmaceuticals, Inc. 2016-02-01 Phase 3 NCT01978938 Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections